Controversies in the Management of Advanced Melanoma: “Gray” Areas Amid the “Black and Blue”

Annals of Pharmacotherapy

Volumn 48, Issue 11, 2014, Pages 1456-1468

  Jarkowski, Anthony ^a   Norris, LeAnn ^b   Trinh, Van Anh ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b University of South Carolina   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

advanced melanoma; BRAF inhibitor; cytotoxic T lymphocyte antigen 4; dabrafenib; ipilimumab; MEK inhibitor; trametinib; treatment sequencing; vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MONOCLONAL ANTIBODY; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER RESISTANCE; CENTRAL SEROUS RETINOPATHY; COLITIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; ENDOCRINE DISEASE; FATIGUE; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATITIS; HUMAN; HYPERKERATOSIS; HYPERTENSION; IMMUNOTHERAPY; MELANOMA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PHOTOSENSITIVITY DISORDER; RASH; RETINA VEIN OCCLUSION; REVIEW; SKIN CARCINOMA; TREATMENT PLANNING; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; PATHOLOGY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; INDOLES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84908092309     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014544165     Document Type: Review

References (69)

1. Siegel R,Ma J,Zou Z,.Cancer statistics, 2014.CA Cancer J Clin. 2014;64:9-29
2. Miller AJ,Mihm MC.Melanoma.N Engl J Med. 2006;355:51-65
3. Korn EL,Liu PY,Lee SJ,.Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.J Clin Oncol. 2008;26:527-534
4. Agarwala SS.Current systemic therapy for metastatic melanoma.Expert Rev Anticancer Ther. 2009;9:587-595
5. Middleton MR,Grob JJ,Aaronson N,.Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.J Clin Oncol. 2000;18:158-166
6. Margolin K,Atkins B,Thompson A,.Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.J Cancer Res Clin Oncol. 2002;128:214-218
7. Atkins MB,Lotze MT,Dutcher JP,.High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.J Clin Oncol. 1999;17:2105-2116
8. Chapman PB,Einhorn LH,Meyers ML,.Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.J Clin Oncol. 1999;17:2745-2751
9. Atkins MB,Hsu J,Lee S,.Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.J Clin Oncol. 2008;26:5748-5754
10. Bedikian AY,Johnson MM,Warneke CL,.Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.J Immunotoxicol. 2008;5:201-207
11. Egen JG,Kuhns MS,Allison JP.CTLA-4: new insights into its biological function and use in tumor immunotherapy.Nat Immunol. 2002;3:611-618
12. Davies H,Bignell GR,Cox C,.Mutations of the BRAF gene in human cancer.Nature. 2002;417:949-954
13. Yervoy® (Ipilimumab) [US prescribing information]. Princeton, NJ: Bristol-Myers Squibb. http://packageinserts.bms.com/pi/pi_yervoy.pdf. Accessed April 6, 2014.
14. Zelboraf® (Vemurafenib) [US prescribing information]. South San Francisco, CA: Genentech USA, Inc. http://www.gene.com/download/pdf/zelboraf_prescribing.pdf. Accessed April 6, 2014.
15. Tafinlar® (Dabrafenib) [US prescribing information]. Research Triangle Park, NC: GlaxoSmithKline. http://us.gsk.com/products/assets/us_tafinlar.pdf. Accessed April 6, 2014.
16. Mekinist® (Trametinib) [US prescribing information]. Research Triangle Park, NC: GlaxoSmithKline. http://us.gsk.com/products/assets/us_mekinist.pdf. Accessed April 6, 2014.
17. Trinh VA,Hwu WJ.Ipilimumab in the treatment of melanoma.Exp Opin Biol Ther. 2012;12:773-782
18. Hodi FS,O’Day SJ,McDermott DF,.Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010;363:711-723
19. Robert C,Thomas L,Bondarenko I,.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.N Engl J Med. 2011;364:2517-2526
20. Weber JS,Kahler KC,Hauschild A.Management of immune-related adverse events and kinetics of response with ipilimumab.J Clin Oncol. 2012;30:2691-2697
21. Amer MH,Al-Sarraf M,Baker LH,.Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.Cancer. 1978;42:660-668
22. Davies MA,Liu P,McIntyre S,.Prognostic factors for survival in melanoma patients with brain metastases.Cancer. 2011;117:1687-1696
23. Fife KM,Coleman MH,Stevens GN,.Determinants of outcome in melanoma patients with cerebral metastases.J Clin Oncol. 2004;22:1293-1300
24. Margolin K,Ernstoff MS,Hamid O,.Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.Lancet Oncol. 2012;13:459-465
25. Jakob JA,Bassett RL,Ng CS,.NRAS mutation status is an independent prognostic factor in metastatic melanoma.Cancer. 2012;118:4014-4023
26. Long GV,Menzies AM,Nagrial AM,.Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.J Clin Oncol. 2011;29:1239-1246
27. Chapman PB,Hauschild A,Robert C,.Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med. 2011;364:2507-2516
28. McArthur GA,Chapman PB,Robert C,.Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomized, open-label study.Lancet Oncol. 2014;15:323-332
29. Dummer R,Goldinger SM,Turtschi CP,.Vemurafenib in patients with BRAFV600 mutation-positive melanoma patients with symptomatic brain metastases: final results of an open-label pilot study.Eur J Cancer. 2014;50:611-621
30. Hauschild A,Grobb JJ,Demidov LV,.Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial.Lancet. 2012;380:358-365
31. Long GV,Trefzer U,Davies MA,.Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicenter, open-label, phase 2 trial.Lancet Oncol. 2012;13:1087-1095
32. Flaherty KT,Robert C,Hersey P,.Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med. 2012;367:107-114
33. Schadendorf D,Flaherty KT,Hersey P,.Overall survival update on METRIC, a randomized phase 3 study to assess efficacy of trametinib compared with chemotherapy in patients with BRAFV600E/K mutation-positive advanced or metastatic melanoma.Pigment Cell Melanoma Res. 2013;26:997
34. Kim KB,Kefford R,Pavlick AC,.Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without BRAF inhibitor.J Clin Oncol. 2013;31:482-489
35. Flaherty KT,Infante JR,Daud A,.Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med. 2012;367:1694-1703
36. COMBI-d data summary. Research Triangle Park, NC: GlaxoSmithKline. http://www.gsk-clinicalstudyregister.com/study/115306. Accessed April 18, 2014.
37. RED BOOK Online®. Truven Health Analytics Inc. http://www.micromedexsolutions.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/D444E2/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/FFA8BF/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.FindRedBook. Accessed April 18, 2014.
38. Sosman JA,Daud A,Weber JS,.BRAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib in BRAF inhibitor-naïve and BRAF inhibitor-resistant patients with BRAF mutation-positive metastatic melanoma.J Clin Oncol. 2013;31:
39. McDermott D,Haanen J,Chen TT,.Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).Ann Oncol. 2013;24:2694-2698
40. Maio M,Bondarenko I,Robert C,.Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma.Abstract presented at: European Cancer Congress 2013; Amsterdam, Netherlands;.
41. Prieto PA,Yang JC,Sherry RM,.CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.Clin Cancer Res. 2012;18:2039-2047
42. Schadendorf D,Hodi FS,Robert C,.Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma.Abstract presented at: European Cancer Congress> 2013; Amsterdam, Netherlands;.
43. Wagle N,Emery C,Berger MF,.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.J Clin Oncol. 2011;29:2085-2096
44. Fisher R,Ali Z,Edmonds K,.Clinical behavior of metastatic melanoma after progression on vemurafenib.Pigment Cell Melanoma Res. 2012;25:856
45. Ackerman A,Klein O,McDermott DF,.Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors.Cancer. 2014;120:1695-1701
46. Ascierto PA,Simeone E,Sileni VC,.Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.Cancer Invest. 2014;32:144-149
47. Sosman JA,Kim KB,Schuchter L,.Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med. 2012;366:707-714
48. Ascierto PA,Minor D,Ribas A,.Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.J Clin Oncol. 2013;31:3205-3211
49. Wilmott JS,Long GV,Howle JR,.Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.Clin Cancer Res. 2012;18:1386-1394
50. Frederick DT,Piris A,Cogdill AP,.BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.Clin Cancer Res. 2013;19:1225-1231
51. Jiang X,Zhou J,Giobbie-Hurder A,.The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.Clin Cancer Res. 2013;19:598-609
52. Larkin J,Del Vecchio M,Ascierto PA,.Vemurafenib in patients with BRAF (V600) mutated metastatic melanoma: an open-label, multicenter, safety study.Lancet Oncol. 2014;15:436-444
53. Schwartzentruber DJ.Guidelines for the safe administration of high-dose interleukin-2.J Immunother. 2001;24:287-293
54. Kammula US,White DE,Rosenberg SA.Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.Cancer. 1998;83:797-805
55. Kaufman HL,Kirkwood JM,Hodi FS,.The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment if cutaneous melanoma.Nat Rev Clin Oncol. 2013;10:588-598
56. Joseph RW,Eckel-Passow JE,Sharma R,.Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2.J Immunother. 2012;35:711-715
57. Smith FO,Goff SL,Klapper JA,.Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.J Immunother. 2007;30:130
58. Heimann DM,Schwartzentruber DJ.Gastrointestinal perforations associated with interleukin-2 administration.J Immunother. 2001;24:287-293
59. Sullivan RJ,Flaherty KT.Resistance to BRAF-targeted therapy on melanoma.Eur J Cancer. 2013;49:1297-1304
60. Das Thakur M,Stuart DD.The evolution of melanoma resistance reveals therapeutic opportunity.Cancer Res. 2013;73:6106-6110
61. Yadav V,Zhang X,Liu J,.Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.J Biol Chem. 2012;287:28087-28098
62. Wilson TR,Fridlyand J,Yan Y,.Wide-spread potential for growth-factor-driven resistance to anticancer kinase inhibitors.Nature. 2012;487:505-509
63. Straussman R,Morikawa T,Shee K,.Tumor-microenvironment elicits innate resistance to RAF inhibitors through HGF secretion.Nature. 2012;487:500-504
64. Von Minckwitz G,Du Bois A,Schmidt M,.Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study.J Clin Oncol. 2009;27:1999-2006
65. Riely GJ,Kris MG,Zhao B,.Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.Clin Cancer Res. 2007;13:5150-5155
66. Kang YK,Ryu MH,Yoo C,.Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised placebo-controlled, phase 3 trial.Lancet Oncol. 2013;14:1175-1182
67. Das Thakur M,Salangsang F,Landman AS,.Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.Nature. 2013;494:251-255
68. Seghers AC,Wilgenhof S,Lebbé C,Neyns B.Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.Melanoma Res. 2012;22:466-472
69. Wagle N,Van Allen EM,Treacy DJ,.MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Cancer Discov. 2014;4:61-68